GO
| HSI1 | 21,980.74 | +70.98 | 208.04B |
| HSCEI1 | 8,080.54 | +23.69 | 83.92B |
| Back Zoom + Zoom - Block Traded | |
|
2025-04-25 14:45:03 In February 2025, INNOVENT BIO (01801.HK) recorded sales of RMB179 million and RMB114 million for its products sintilimab and bevacizumab, up 47.6% and 32.3% YoY respectively, according to a report from BofA Securities. The company's sales of rituximab also rose by 15.4% YoY to RMB51.5 million. In addition, its sales of selpercatinib and tafolecimab surged by 53.2% and 2.13x YoY, respectively. In light of the strong sales performance of the company's core products, the broker raised its 2025-26 sales forecasts for the company by 1%. BofA Securities added its target price for INNOVENT BIO from $52 to $61.1 and reiterated the Buy rating, considering its robust sales performance and solid product pipeline. ~ AAStocks Financial News Web Site: www.aastocks.com | |